Aster DM Healthcare Limited has announced a scheduled meeting with analysts and institutional investors, informing both BSE and NSE stock exchanges in compliance with regulatory requirements.

Meeting Details

The healthcare company has provided specific details about the upcoming investor engagement:

Regulatory Compliance

The announcement was made pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Hemish Purushottam signed the notification on March 23, 2026.

Important Disclosures

The company has made several key disclosures regarding the meeting:

• No unpublished price sensitive information will be shared during the investor meetings
• The schedule may undergo changes due to exigencies on the part of investors, analysts, or the company
• The meeting is organized by ICICI Securities Limited

Corporate Information

Aster DM Healthcare Limited maintains its registered office in Hyderabad, Telangana, while its corporate office is located in Bengaluru, Karnataka. The company's stock is listed on both BSE and NSE exchanges.

This investor meeting represents part of the company's ongoing engagement with the investment community and analysts, providing a platform for management to interact with stakeholders while maintaining compliance with securities regulations.

Aster DM Healthcare has received a positive rating revision from Kotak Institutional Equities, which has reinstated its Add recommendation on the healthcare provider with an ambitious target price of ₹725.

Growth Projections Post Quality Care Merger

The brokerage firm expects strong financial performance following the completion of the Quality Care merger, projecting robust growth metrics for the combined entity.

Key Growth Drivers

Kotak's optimistic outlook is supported by several strategic advantages that the merged entity is expected to leverage:

• Operational Synergies: Enhanced efficiency through combined operations and shared resources
• Enhanced Oncology Services: Strengthened cancer care capabilities driving higher revenue per patient
• Improved Payor Mix: Better insurance and corporate client portfolio leading to improved realizations
• Reduced ALOS: Lower Average Length of Stay indicating operational efficiency improvements
• Strong Balance Sheet: Robust financial position supporting growth initiatives

Expansion Strategy and Capacity Addition

The company's growth strategy includes significant capacity expansion through a well-planned bed addition program. Aster DM Healthcare plans to add 4,342 beds to its existing network, with approximately 60% of this expansion coming through brownfield projects.

This expansion approach, with its emphasis on brownfield development, is expected to provide faster implementation timelines and better return on investment compared to greenfield projects. The strategic bed addition program positions the healthcare provider for sustained growth over the coming years, supporting Kotak's positive long-term outlook on the stock.